

## Special Issue

# Immunology of Hodgkin Lymphoma

### Message from the Guest Editor

Hodgkin Lymphoma (HL) is a cancer of lymph nodes and is commonly diagnosed in adolescents and young adults. It is characterized by a minority of tumor cells, called Hodgkin and Reed–Sternberg (HRS) cells, that are surrounded by a large number of reactive immune cells. The HRS cells originate from germinal center B-cells and are highly aberrant. It is hard to understand how they can develop within lymph nodes, especially in young and otherwise healthy individuals. This is even more apparent in cases in which the immunogenic Epstein–Barr-virus (EBV) is present in the tumor cells. Not only do (precursor) HRS cells escape from a multitude of anti-tumor immune responses, they even shape and hijack the tumor microenvironment (TME) for their own benefit. This may explain why novel treatments like immune checkpoint inhibitors that target the TME are highly effective in HL. You are invited to contribute original research to this Issue on the Immunology of HL. The main theme is the cross-talk between (cells of) the TME and (precursor) HRS cells. Manuscripts on immunology related blood biomarkers and genetic susceptibility are also invited.

### Guest Editor

Dr. Arjan Diepstra

Department of Pathology and Medical Biology, University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands

### Deadline for manuscript submissions

closed (31 January 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/75024](https://mdpi.com/si/75024)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)